Angiogenesis

The European Commission ( EC ) has granted marketing authorization for Stivarga ( Regorafenib ) for the treatment of adult...


Renal cell carcinoma ( RCC ) accounts for approximately 330,000 cases diagnosed each year and 140,000 deaths worldwide. Most cases are...


Top-line results from the CABOSUN randomized phase 2 trial of Cabozantinib ( Cabometyx; Cometriq ) in patients with previously untreated...


Clear cell renal cell carcinoma ( ccRCC ) is well known for its hypervascularity due to the Von Hippel-Lindau/hypoxia-inducible factor...


The Committee for Medicinal Products for Human Use ( CHMP ), the scientific committee of the European Medicines Agency ( EMA...


Eylea ( Aflibercept ) injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (...


Lenvatinib ( Lenvima ) is an orally administered multiple receptor tyrosine kinase ( RTK ) inhibitor with a novel binding...


Eli Lilly has announced that the FDA ( Food and Drug Administration ) has approved Cyramza ( Ramucirumab ) as...


The FDA ( Food and Drug Administration ) has accepted for priority review the supplemental biologics license application ( sBLA...


The European Commission ( EC ) has approved Cometriq ( Cabozantinib ) for the treatment of adult patients with progressive,...


Inflammation is an important feature of the malignant phenotype and promotes angiogenesis, tumour invasiveness, metastases, and cachexia. Researchers used a...


Eli Lilly has announced that the REVEL trial, a global phase III study of Ramucirumab in combination with chemotherapy in...


Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the...


Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the...


The European Commission has granted EU marketing authorisation for Vargatef ( Nintedanib ). Vargatef in combination with Docetaxel ( Taxotere...


Scientific literature suggests a potential association between vascular endothelial growth factor ( VEGF ) receptor inhibition and thrombotic microangiopathy (...


Glioblastoma ( GBM ) is the most common primary malignant adult brain tumor and, despite treatment advances in recent years,...


Eylea ( Aflibercept ) injection has been approved by the European Commission for the treatment of visual impairment due to...


Stivarga ( Regorafenib ) has been approved by the European Commission ( EC ) for the treatment of adult patients...


In September 2014, the FDA ( Food and Drug Administration ) granted Eylea ( Aflibercept ) injection Breakthrough Therapy designation...